GlobeNewswire Inc | Nov 4, 2021 06:01AM EDT

November 04, 2021

EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today reported financial results for the quarter ended September30, 2021.

Recent Highlights

-- Grew total revenue to a record of $24.3 million for the third quarter of 2021, representing 34% growth compared to the third quarter of 2020 -- Placed 13 new systems and increased installed base to 105 Berkeley Lights platforms, including 6 placements to existing customers in the third quarter of 2021Genovac purchased a third Beacon Optofluidic system, becoming the first CRO to leverage the Beacon system for both antibody discovery and cell line development GlaxoSmithKline purchased a third Beacon Optofluidic system to expand its antibody therapeutics capacity -- Expanded Biofoundry capacity with a new Boston lab to support the continued growth in the services and partnerships businesses -- Appointed Siddhartha Kadia, Ph.D. to the Board of Directors as an independent director, adding his significant expertise in commercializing disruptive life science technologies

Our performance this quarter speaks to the increasing demand for our technology and services across large, global markets, said Berkeley Lights Chief Executive Officer Eric Hobbs, Ph.D. These results reflect our growing success in developing disruptive workflows and services vital to our customers efforts to unlock revolutionary improvements to human health. We are well-positioned to continue accelerating scientific breakthroughs, creating value for our customers and our shareholders.

Quarterly 2021 Financial Results

Three Months Ended September 30,(in thousands, except per share data) 2021 2020 (unaudited) (unaudited)Revenue $ 24,324 $ 18,208 Gross profit 15,413 12,808 Gross margin % 63 % 70 %Operating expenses 35,393 20,991 Loss from operations (19,980) (8,183) Net loss and net comprehensive loss (20,403) (8,601) Net loss attributable to common stockholders per share, (0.30) (0.16) basic and dilutedTotal stock-based compensation 5,962 2,535

2021 Outlook

Berkeley Lights expects full year 2021 revenue to be in the low $90 million range.

Webcast and Conference Call Information

Berkeley Lights will host a conference call to discuss the third quarter 2021 financial results before market open on Thursday, November 4, 2021 at 5:30 a.m. Pacific Time/8:30 a.m. Eastern Time. A webcast of the conference call can be accessed at http://investors.berkeleylights.com. The webcast will be archived and available for replay for at least 90 days after the event.

About Berkeley Lights

Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.

Berkeley Lights Beacon and Lightning systems and Culture Station instrument are: FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Forward Looking Statements

This press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

MediaContactmedia@berkeleylights.com

Investor Contactir@berkeleylights.com

Berkeley Lights, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share data)

Three months ended September Nine months ended June 30, 30, 2021 2020 2021 2020 Revenue: Product revenue $ 16,704 $ 14,103 $ 43,258 $ 33,893 Service revenue 7,620 4,105 18,944 8,662 Total revenue 24,324 18,208 62,202 42,555 Cost of sales: Product cost of 4,797 3,463 11,832 8,467 salesService cost of 4,114 1,937 9,778 4,339 salesTotal cost of 8,911 5,400 21,610 12,806 salesGross profit 15,413 12,808 40,592 29,749 Operating expenses:Research and 16,195 10,421 42,757 33,240 developmentGeneral and 12,258 7,229 32,950 15,419 administrativeSales and 6,940 3,341 17,863 9,651 marketingTotal operating 35,393 20,991 93,570 58,310 expensesLoss from (19,980) (8,183) (52,978) (28,561) operationsOther income (expense):Interest expense (232) (361) (942) (1,074) Interest income 33 51 142 249 Other income (170) 10 (117) 72 (expense), netLoss before (20,349) (8,483) (53,895) (29,314) income taxesProvision for 54 118 97 142 income taxesNet loss and netcomprehensive $ (20,403) $ (8,601) $ (53,992) $ (29,456) loss Net lossattributable tocommon $ (0.30) $ (0.16) $ (0.81) $ (1.56) stockholders pershare, basic anddilutedWeighted-averageshares used incalculating net 67,213,282 53,596,982 66,428,303 20,041,080 loss per share,basic anddiluted

Berkeley Lights, Inc. Condensed Consolidated Balance Sheets(In thousands, except share and per share data)

September December 31,Assets 30, 2020 2021 (unaudited) Current assets: Cash and cash equivalents $ 197,001 $ 233,408 Trade accounts receivable 24,713 12,939 Inventory 13,210 11,047 Prepaid expenses and other current assets 10,988 8,175 Total current assets 245,912 265,569 Restricted cash 270 270 Property and equipment, net 24,999 14,544 Operating lease right-of-use assets 26,785 16,718 Other assets 3,188 2,557 Total assets $ 301,154 $ 299,658 Liabilities and Stockholders? Equity Current liabilities: Trade accounts payable $ 12,822 $ 3,491 Accrued expenses and other current liabilities 10,210 8,401 Current portion of notes payable ? 11,594 Deferred revenue 11,282 5,482 Total current liabilities 34,314 28,968 Notes payable, net of current portion 19,746 8,301 Deferred revenue, net of current portion 1,819 1,709 Operating lease liability, noncurrent 25,090 15,899 Total liabilities 80,969 54,877 Stockholders? equity: Convertible preferred stock ? ? Common stock 4 3 Additional paid-in capital 466,057 436,662 Accumulated deficit (245,876) (191,884) Total stockholders? equity 220,185 244,781 Total liabilities and stockholders? equity $ 301,154 $ 299,658